Correction to: Belsey JD. Switch strategies in the management of hypertension: a cost minimisation analysis of angiotensin receptor blocker based regimen. Curr Med Res Opin 2008;24:581–89.

By  

Current Medical Research and Opinion, Vol. 24, Iss. 7, 2008-07 ,pp. : 1975-1975

Informa Healthcare

Access to resources Recommend Favorite

Optimising immune tolerance induction strategies in the management of haemophilia patients with inhibitors: a cost-minimisation analysis

By Odeyemi Isaac A. O.   Danø Anne M.  

Current Medical Research and Opinion, Vol. 25, Iss. 1, 2009-01 ,pp. : 239-250

Informa Healthcare

Access to resources Recommend Favorite

Serum Levels of the Advanced Glycation End Products N^ε-Carboxymethyllysine and Pentosidine Are Not Influenced by Treatment with the Angiotensin Receptor II Type 1 Blocker Irbesartan in Patients with Type 2 Diabetic Nephropathy and Hypertension

By  

Nephron Clin Pract, Vol. 108, Iss. 4, 2008-04 ,pp. : c291-c297

Karger

Access to resources Recommend Favorite

The Association between Angiotensin Receptor Blocker Usage and Breast Cancer Characteristics

By  

Oncology, Vol. 91, Iss. 4, 2016-08 ,pp. : 217-223

Karger

Access to resources Recommend Favorite

Treatment of angiotensin receptor blocker‐induced Angioedema: A case series

By  

THE LARYNGOSCOPE, Vol. 125, Iss. 7, 2015-07 ,pp. : 1619-1623

John Wiley & Sons Inc

Access to resources Recommend Favorite